Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4856422 | 0.86 | OPRM1 (0.57) | LMNAOPRM1OPRK1OPRD1 | |
| SCHEMBL4851605 | 0.83 | OPRM1 (0.41) | EGFROPRM1OPRK1KDM4EOPRD1 | |
| SCHEMBL4856520 | 0.82 | CACNA1G (0.41) | CACNA1GLMNAEGFRKDM4E | |
| SCHEMBL14279575 | 0.82 | CACNA1G (0.44) | CACNA1GLMNAEGFRKDM4E | |
| SCHEMBL4858840 | 0.81 | OPRM1 (0.47) | CACNA1GOPRM1OPRK1KDM4E | |
| SCHEMBL14279567 | 0.81 | CACNA1G (0.40) | CACNA1GLMNAEGFRKDM4E | |
| SCHEMBL17141680 | 0.81 | L3MBTL1 (0.37) | LMNAOPRM1OPRD1 | |
| Potassium Ion SCHEMBL4853484 | 0.81 | BLM (0.42) | OPRM1OPRK1OPRD1 | |
| SCHEMBL14279557 | 0.80 | NR1H2 (0.43) | CACNA1GKDM4E | |
| SCHEMBL14279558 | 0.79 | KDM4E (0.43) | CACNA1GLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314879-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7186715-B2 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186715-B2 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| US-7169777-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-7157463-B2 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1469851-B1 | MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2006-10-11 | — | — | EP | disclosed |
| EP-1370558-B1 | PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-1368340-B1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040092507-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-05-13 | — | — | US | disclosed |
| US-20040082590-A1 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-04-29 | — | — | US | disclosed |
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-03-25 | — | — | US | disclosed |
| EP-1370558-A1 | PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1368340-A1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1368339-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | Eli Lilly & Company (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003061660-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2002059107-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002059108-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002059117-A1 | PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092507-A1 | Melanocortin receptor agonists | MC1R, MC4R, MC5R | CACNA1G 2858/4885LMNA 4634/4885EGFR 2633/4885 |
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | MC1R, MC4R, MC5R | CACNA1G 2010/4885LMNA 4580/4885EGFR 3418/4885 |
| US-20040082590-A1 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | MC1R, MC4R, MC5R | CACNA1G 2194/4885LMNA 4588/4885EGFR 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.